Category: Zacks Small Cap Research

1525354555667540 / 663 POSTS
By John Vandermosten, CFANASDAQ:TENXLevosimendan is a calcium sensitizer and K-ATP channel activator that can improve systolic and diastolic function of the heart as well as provide vasodilatory effects through its ability to relax vascular smooth mu ...
By John Vandermosten, CFANASDAQ:ATXIAvenue Therapeutics (NASDAQ:ATXI) is developing IV tramadol for postoperative pain. The drug has been approved by the FDA since 1995; however, only in oral form. Avenue has licensed a patented administration of IV ...
By Lisa ThompsonOTC:AFOMWe are initiating coverage of All For One Media (OTC:AFOM) is a media and entertainment company created to market to the tween demographic. Its initial focus is to create a franchise around the release of Crazy For The Boys, a ...
By John Vandermosten, CFANASDAQ:CRME2017 Full Year Operational and Financial ResultsCardiome Pharma Corp. (NASDAQ:CRME) issued a press release reporting 2017 full-year results on March 13, 2018, and filed its 2017 financial statements and management ...
By David Bautz, PhDTSX:ATE.VFinancial UpdateOn April 3, 2018, Antibe Therapeutics Inc. (TSX:ATE.V) announced that following the successful completion of the Phase 2b gastrointestinal safety study and release of positive topline results, the company h ...
By John Vandermosten, CFANASDAQ:RXIIOn March 26, 2018, RXi Pharmaceuticals (NASDAQ:RXII) reported fourth quarter and full year 2017 results in conjunction with the filing of their 2017 10-K. RXi reported revenues of $15,000 for the year from grants r ...
By Anita DushyanthNASDAQ:MYOSHeadquartered in Cedar Knolls, NJ, MYOS RENS Technology Inc. (NASDAQ:MYOS) is an emerging advanced nutrition and biotherapeutics company. Their business is focused on developing and commercializing nutritional supplements ...
By John Vandermosten, CFANASDAQ:LPCN2017 Operational and Financial ResultsLipocine Inc. (NASDAQ:LPCN) filed its 2017 10-K and posted its earnings release on March 12, summarizing an volatile year which included new dosing studies for Tlando and a res ...
By Lisa ThompsonNASDAQ:CSSESince the acquisition of Screen Media on November 3rd of last year, Chicken Soup for the Soul Entertainment (NASDAQ:CSSE) has moved from being strictly a producer of original content, to a content distributor and web based ...
By Brian Marckx, CFANASDAQ:VIVEViveve (NASDAQ:VIVE) reported Q4 2017 results and provided a business update. Management also reiterated their previously issued 2018 revenue guidance in the range of $22M and $24M (inline with our prior and current ex ...
1525354555667540 / 663 POSTS